Other proposed lung cancer biogenetic markers are HER‐2/neu overexpression which is identified as a significant contributor to the development and progression of lung cancer in patients with CLL [16]; this is in contrast to our cases, whose histological analysis of the lung mass was negative for HER‐2/neu overexpression. The gene discussed is ERBB2; the disease is B-cell chronic lymphocytic leukemia.